Org. age Ohio . 711 - The Ohio State University

College Publications 2005-06
2005 Division of Medicinal Chemistry and Pharmacognosy
J.C. Hackett, R.W. Brueggemeier, and C.M. Haddad, The final catalytic step of cytochrome P450 aromatase: A
density functional theory study. J. Am. Chem. Soc., 127, 5224-5237 (2005).
E.S. Diaz-Cruz, C.L. Shapiro, and R.W. Brueggemeier, Cyclooxygenase inhibitors suppress aromatase expression
and activity in breast cancer cells. J. Clin. Endocrinol. Metab., 90, 2563-2570 (2005).
R.W. Brueggemeier, J.C. Hackett, and E.S. Diaz-Cruz, Aromatase Inhibitors for the Treatment of Breast Cancer.
Endocrine Reviews, 26, 331-345 (2005).
J.C Hackett, Y.-W. Kim, B. Su, and R.W. Brueggemeier, Synthesis and characterization of azole isoflavone
inhibitors of aromatase. Bioorg. Med. Chem., 13, 4063-4070 (2005).
R.W. Brueggemeier, E.S. Díaz-Cruz, P.-K. Li, Y. Sugimoto, Y.C. Lin, C.L. Shapiro, Translational studies on
aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J. Steroid Biochem. Molec. Biol., 95, 129-136
(2005).
B. Su, J.C Hackett, E.S. Díaz-Cruz, Y.-W. Kim, and R.W. Brueggemeier, Lead optimization of 7-benzyloxy 2-
(4’-pyridylmethylthio) isoflavone aromatase inhibitors. Bioorg. Med. Chem., 13, 6571-6577 (2005).
R.W. Brueggemeier, “Sex Hormones (Male), Analogs, and Antagonists” in Encyclopedia of Molecular Cell Biology
and Molecular Medicine, Volume 13, R.A. Meyers, Editor-in-Chief, Wiley-VCH Verlag GmbH & Co., Weinheim,
Germany, 1-69, 2005.
J.-W. Huang, C.-W. Shiau, Y.-T. Yang, K.-F. Chen, S. K. Kulp, R. W. Brueggemeier, C. L. Shapiro, and C.-S.
Chen (2005) “Peroxisome Proliferator-Activated Receptor g-Independent Ablation of Cyclin D1 by
Thiazolidenediones and Their Derivatives in Breast Cancer Cells” Mol Pharmacol, 67, 1342-1348
A. J. Johnson, L. L. Smith, J. Zhu, N. A., Heerema, S. Jefferson, M. R. Grever, C.-S. Chen, J. C. Byrd (2005) “A
novel celecoxib derivative inducesapoptosis in primary CLL cells and transformed B-cll lymphoma via a caspaseand
Bcl-2-independent mechanism” Blood, 105, 2504-2509
H. Ding, C. Han, J. Zhu, C.-S. Chen, and S. M. D'Ambrosio (2005) “Celecoxib derivatives induce apoptosis via
the disruption of mitochondrial membrane potential and activation of caspase 9” Int. J. Cancer, 113, 803-810.
C.-W. Shiau, C.-C. Yang, K.-F. Chen, J.-W. Huang, and C.-S. Chen (2005) “Thiazolidenediones mediates
apoptosis in prostate cancer cells, in part, via the inhibition of Bcl-xL/Bcl-2 functions independently of PPARg”
Cancer Res., 65, 1561-1569.
P.-H. Tseng, H.-P. Lin, K.-F. Chen, J. Zhu, J.C C. Byrd, M. R. Grever, B. J. Druker, and C.-S. Chen (2005)
“synergistic interactions between imatinib and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-
03012 in overcoming imatinib resistance” Blood, 105, 4021-4027.
O.S. Gardner, C.-W. Shiau, C.-S. Chen, and L.M. Graves (2005) “PPARg-independent activation of p38 MAPK
by thiazolidebediones involves calcium/calmodulin-dependent protein kinase II and protein kinase R: correlation
with endoplasmic reticulum stress” J. Biol. Chem., 280, 10109-10118.
C,-S, Chen, S.-C. Weng, P.-H. Tseng, H.-P. Lin, and C.-S. Chen (2005) “Nonepigenetic effects of histone
deacetylase inhibitors on Akt through reshuffling protein phosphatae-1 complexes” J. Biol. Chem, 280, 38879-
38887.
Q. Lu, D.-S. Wang, C.-S. Chen, Y.D. Hu, and C.-S. Chen (2005) “Structure-based optimization of
phenylbutyrate-derived histone deacetylase inhibitors” J. Med. Chem. 48, 5530-5535.
S. K. Kulp, K.-F. Chen, and C.-S. Chen (2005) “Chemotherapy for prostate cancer” in Prostate Cancer. Basic
mechanisms and Therapeutic Approaches (Ed., C. Chang) World Scientific, New Jersey, pp. 365-82
J.E. Kucab, C. Lee, C.-S. Chen, J. Zhu, C. B. Gilks, M. Cheang, D. Huntsman, E. Yorida, J. Emerman, M.
Pollak, S. E. Dunn (2005) Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary
breast tumours Breast Cancer Research 2005, 7:R796-R807
37